Achillion Pharmaceuticals Inc. (ACHN)

3.13
0.07 2.00
NASDAQ : Health Technology
Prev Close 3.20
Open 3.15
Day Low/High 3.14 / 3.22
52 Wk Low/High 2.58 / 5.66
Volume 1.14M
Avg Volume 2.28M
Exchange NASDAQ
Shares Outstanding 137.86M
Market Cap 405.30M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week Of February 2018 Options Trading For Achillion Pharmaceuticals (ACHN)

First Week Of February 2018 Options Trading For Achillion Pharmaceuticals (ACHN)

Investors in Achillion Pharmaceuticals Inc saw new options become available this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACHN options chain for the new February 2018 contracts and identified the following call contract of particular interest.

Short Interest Moves 18.3% Lower For ACHN

Short Interest Moves 18.3% Lower For ACHN

The most recent short interest data has been released for the 11/30/2017 settlement date, which shows a 1,585,169 share decrease in total short interest for Achillion Pharmaceuticals Inc. , to 7,056,852, a decrease of 18.34% since 11/15/2017.

First Week of June 2018 Options Trading For Achillion Pharmaceuticals (ACHN)

Investors in Achillion Pharmaceuticals Inc. saw new options become available this week, for the June 2018 expiration.

Achillion Reports Third Quarter 2017 Financial Results And Provides Update On Clinical Programs

Achillion Reports Third Quarter 2017 Financial Results And Provides Update On Clinical Programs

Robust balance sheet to support global expansion of ACH-4471 clinical development program in PNH and C3G

Achillion Announces Presentation Of Data From OMEGA-1 Phase 2b Trial With Odalasvir, AL-335, And Simeprevir (JNJ-4178) At The 2017 Liver Meeting

Achillion Announces Presentation Of Data From OMEGA-1 Phase 2b Trial With Odalasvir, AL-335, And Simeprevir (JNJ-4178) At The 2017 Liver Meeting

- 98.9% SVR12 achieved following six weeks of therapy for patients with chronic HCV genotypes 1, 2, 4, 5, or 6 -

Johnson & Johnson Shuts Insulin Pump Business, Inks Other Deals

Johnson & Johnson Shuts Insulin Pump Business, Inks Other Deals

Healthcare giant Johnson & Johnson cut costs by laying off 297 staffers tied to its insulin pump business, while also buying a German surgical software company and inking a deal with biotech company targeting hepatitis B treatments.

S&P 500 Reaches New Record as Stocks Rally Amid Subsiding Irma, North Korea Fears

S&P 500 Reaches New Record as Stocks Rally Amid Subsiding Irma, North Korea Fears

Wall Street starts the week with a rally.

Dow, S&P 500 on Track for Best Day in 6 Months as Irma Worries Ease

Dow, S&P 500 on Track for Best Day in 6 Months as Irma Worries Ease

The Dow is up more than 250 points.

Dow Trades Above 22,000 as Irma's Damage Estimates Lower Than Feared

Dow Trades Above 22,000 as Irma's Damage Estimates Lower Than Feared

Wall Street moves higher.

Achillion Shares Are Plunging on Termination of Hepatitis C Pact

Achillion Shares Are Plunging on Termination of Hepatitis C Pact

The New Haven, Conn.-based firm on Sept. 9 received a termination notice regarding its license and collaboration pact with Johnson & Johnson's Janssen Pharmaceuticals Inc. on hepatitis C.

Achillion Pharmaceuticals Stock Falls, Baird Downgrades Over Lack of Confidence

Achillion Pharmaceuticals Stock Falls, Baird Downgrades Over Lack of Confidence

Thursday's downgrade is in part based on a lack of confidence in Achillion's CH-4471 to compete with Alexion Pharmaceuticals' Soliris treatment.

These Two Biotech Stocks Are Going Berserk on Wednesday

These Two Biotech Stocks Are Going Berserk on Wednesday

And then there is Mylan.

Achillion To Host Second Quarter 2017 Results Conference Call On August 8, 2017

Achillion To Host Second Quarter 2017 Results Conference Call On August 8, 2017

- Conference call and live webcast will begin at 4:05 p.m. ET on August 8, 2017 -

March 2018 Options Now Available For Achillion Pharmaceuticals (ACHN)

Investors in Achillion Pharmaceuticals Inc. saw new options begin trading today, for the March 2018 expiration.